What is the mechanism of action and therapeutic principle of Quizartinib?

Quizartinib is a selective FLT3tyrosine kinase inhibitor, mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML). FLT3 (Fms-like tyrosine kinase 3) is a receptor tyrosine kinase expressed in bone marrow and peripheral blood, which usually plays an important role in cell proliferation, differentiation and survival. Under normal circumstances, the FLT3 receptor activates downstream signaling pathways by binding to its ligand, helping to regulate the growth of blood cells. However, mutations in the FLT3 gene, especially FLT3-ITD (intron insertion mutations), can lead to sustained activation of the receptor, which in turn triggers abnormal proliferation and survival of leukemia cells.

Quizatinib’s mechanism of action is to selectively inhibit the activity of FLT3 tyrosine kinase and prevent the activation of its downstream signaling pathways. Through this mechanism, quizartinib can effectively prevent the proliferation of FLT3 mutant leukemia cells and induce their apoptosis, thereby achieving a therapeutic effect. Unlike other FLT3 inhibitors, quizartinib has strong selectivity and can efficiently target FLT3 mutant cells while having less impact on normal cells, which makes its therapeutic effect more significant and its side effects relatively mild.

In clinical treatment, quizartinib is often used in patients with relapsed or refractory acute myeloid leukemia, especially those with FLT3 mutation-positive patients. By inhibiting the activity of FLT3, quizatinib can not only slow down the progression of the disease, but also improve the survival of patients. Its use has significantly improved the treatment prospects for patients with FLT3 mutation-positive AML and provided new treatment options for these patients.

In general, quizartinib effectively treats FLT3 mutation-positive acute myeloid leukemia by inhibiting FLT3 tyrosine kinase and blocking its abnormally activated signaling pathways.

Reference materials:https://go.drugbank.com/drugs/DB12874